Dr. Jeffrey Bryan of the University of Missouri explains how the Elias Cancer Immunotherapy works, what the response rates look like, and the types of canine cancers it may treat. He also addresses eligibility, access, and potential side effects.

A new Ardent Animal Health trial is enrolling dogs with osteosarcoma to test a combination immunotherapy using a tumor-derived vaccine and a novel checkpoint inhibitor.